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1. Introduction 
As described previously in this book, hypothermia likely has many positive effects on 
injured brain and spinal cord to limit the damage caused by secondary injury. This 
secondary injury has multiple mechanisms, including inflammation, excitotoxicity, calcium 
homeostasis, blood brain barrier damage, release of toxic intermediates including free 
radicals, as well as cell necrosis & apoptosis (1). Hypothermia has been shown to be an 
effective treatment for comatose survivors of out of hospital cardiac arrest to both improve 
mortality and neurologic outcomes (2, 3). Much less is known about the role of hypothermia 
for treating patients that have suffered an intracerebral or subarachnoid hemorrhage. 
Experience and literature on the subject is quite limited. The same is true for hypothermia in 
the treatment of acute spinal cord injury. In fact, data on this topic is even more limited. 
However, in the coming years it is likely that we will see more research on this important 
topic. The technology available to clinicians for achieving the treatment goals of this strategy 
has rapidly expanded in the past decade. Additionally, its ease of use and increasing 
familiarity amongst clinicians and intensive care unit staff will only help in growing the 
field. The basic science background, while not extensive, is at least encouraging and it is 
expanding. The clinical use, or at least consideration of this therapy is slowly beginning to 
expand as well. Options for medical therapy to improve outcomes in ICH, SAH & SCI are 
limited. Hopefully this continued work will improve upon that. This chapter will explore 
what has been published on these topics to this point. 
2. Therapeutic hypothermia for acute spinal cord injury 
In the 1960’s and 1970’s, multiple investigators published data examining the possibility of 
employing hypothermic therapy to improve outcomes in acute spinal cord injury. At that 
time, most of the studies focused on local cooling via the administration of cold saline to the 
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spinal cord during decompressive laminectomy and durotomy (4-6). However, these studies 
were not rigorous randomized controlled trials and were fraught with multiple 
confounders, such as the concomitant administration of corticosteroids and the potential 
effects of surgery itself (7,8). This, combined with the technical difficulty and invasive nature 
of local cooling, lead to the general abandonment of the idea. 
As technology improved and our understanding of the possible beneficial effects of systemic 
hypothermia grew, so did interest in applying this strategy to the acute spinal cord injury 
patient (9,10). Multiple animal studies have suggested a positive effect of either locally or 
systemically applied therapeutic hypothermia (9). However, clinical experience in the 
modern era is minimal. In 2010, there was a high-profile case of an NFL football player 
suspected to have a spinal cord injury who was treated with systemic hypothermia (11). 
This case garnered the attention of the mass media in addition to the medical community. 
However, it is important to recognize that it is impossible to discern if this patient’s excellent 
outcome can be in any way attributed to therapeutic hypothermia. That case does add to the 
literature describing the safe use of targeted temperature therapy in acute spinal cord injury. 
The largest and most often quoted case series for therapeutic hypothermia in this patient 
population is a retrospective review described by Levi et al in 2009 (12). This group 
describes their institutional experience with therapeutic hypothermia in 14 adult patients 
with acute, complete cervical spinal cord injury who presented to their institution over a 
two year period. Only complete cervical spinal cord injury patients with a GCS 15 were 
considered for their hypothermia treatment protocol. An intravascular cooling device was 
used to achieve and maintain a core body temperature of 33C over a 48 hour period. 
Corticosteroids were not used. All patients underwent surgical intervention. Patients were 
then rewarmed over a 24-32hr period. This group of patients averaged 39.4 years old from a 
range of 16-62years. Induction of hypothermia began within 9.17+/-2.24hr and time to target 
temperature was 2.72+/-0.42hr. They documented a strong correlation between temperature 
and heart rate. Additionally, in one patient, CSF temperature was measured and found to 
closely approximate core temperature. Importantly, none of the 14 patients suffered a life-
threatening adverse event attributable to therapeutic hypothermia. The adverse events 
described were primarily respiratory and closely approximated the type and rate of adverse 
events experienced in an historical control cohort. In a follow-up manuscript, Levi et al 
describe the clinical outcomes of this patient cohort (13). All 14 patients were American 
Spinal Injury Association and International Medical Society of Paraplegia Impairment Scale 
(AIS) A on admission. 8/14 patients remained so, but 3 improved to B, 2 to C and one patient 
had dramatic improvement to AIS D. Importantly, none of the patients worsened. A control 
group of patients only had 3/14 patients improve AIS grade compared with the six in the 
hypothermia group, a non-statistically significant difference. While the low number of 
patients, strict inclusion criteria, observational nature of study and use of an historical 
control may temper enthusiasm for these results, they are nonetheless intriguing and 
provide an excellent basis for developing future studies. 
As mentioned previously, medical therapies for acute spinal cord injury are extremely limited. 
However, with future study, perhaps therapeutic hypothermia’s role in treating the 11,000-
12,000 spinal cord injury patients per year in the United States can further be defined (14). 
 
Hypothermia for Intracerebral Hemorrhage, Subarachnoid Hemorrhage & Spinal Cord Injury 71 
3. Therapeutic hypothermia for intracerebral hemmorhage 
Intracerebral hemorrhage (ICH) accounts for approximately 10% of all cerebral vascular 
accidents in the United States and carries a mortality rate of up to 50% (15,16). Options for 
medical therapy are extremely limited and are primarily focused on supportive therapy (17). 
Mayer et al investigated the potential use of rFVIIa for improving outcome and established 
that this therapy may in fact improve hematoma volume, but its impact on outcomes was 
limited (18). Hematoma volume & growth does correlate with various outcome measures 
(19-21), but so does perihemorrhagic edema (22-25). ICH is associated with secondary injury 
characteristics that are similar to ischemia and ischemia-reperfusion, including blood-brain 
barrier disruption, inflammation and edema. The edema progresses through three phases 
related initially to hydrostatic forces & clot retraction, then activation of the coagulation 
cascade and thrombin formation and later, via RBC lysis and hemoglobin-induced neuronal 
toxicity (26). This edema – termed perihemorrhagic edema – has been associated with poor 
outcomes (22, 23, 25). Data from animal models of ICH suggest that hypothermia can 
improve these injurious processes, but not outcomes (27-33).  
There is a suggestion that the application of therapeutic hypothermia may be beneficial in 
preventing the progression of periphemorrhagic edema and improving outcomes in patients 
who suffer intracranial hemorrhage (34). In a pilot study by Kollmar et al, hypothermia was 
determined to be safe as well as potentially provide a positive effect on ICH 
perihemorrhagic edema (25). This was a comparison of 12 patients w/ supratentorial ICH 
>25mL in volume cooled with an intravascular cooling device to 33 degrees C with 12 
historical controls. Amongst the control cohort, there were more patients with uncontrolled 
intracranial hypertension, perihemorrhagic edema progression and death. In a followup 
study by the same group, Staykov et al described similar findings with 25 patients with 
large ICH as compared with an historical control group (35). Again, perihemorrhagic edema 
remained mostly unchanged in the hypothermia group, but steadily increased in the 
historical control group, with a statistically significant difference in perihemorrhagic edema 
volume. This difference was also associated with a suggestion of mortality difference, but 
with such a small sample size it was not statistically significant. The mortality rate was 8.3% 
in the hypothermia cohort, 16.7% in the control group at 3 months and 28% vs 44% at one 
year. There is a prospective, multicenter, randomized controlled phase II trial currently 
underway to more formally evaluate this question using a similar protocol (36). 
4. Therapeutic Hypothermia for Subarachnoid Hemorrhage 
As in all neurocritical care related illnesses, fever control may be important for minimizing 
secondary injury (37). In subarachnoid hemorrhage, this is particularly true. As many as 
72% of all SAH patients may experience fever (38). Infection should always be ruled out and 
treated aggressively (39); however, the fever needs to be controlled whether it is secondary 
to infection or not. Fever in SAH is strongly linked to poor outcome and increased length of 
stay (40), as well as vasospasm (41, 42), ischemic injury (43), cerebral edema and worsened 
intracranial hypertension (44). Even a single episode of fever has been associated with 
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poorer outcomes. However, one can only definitively say that fever is associated with 
worsened outcomes, it may not be causative. In other words, it may simply be a marker of 
bad outcomes (45).  
Whether fever is simply a marker for bad outcomes or something more, there is a suggestion 
that controlling fever may actually be neuroprotective. Oddo et al demonstrated that 
induced normothermia in 18 SAH patients resulted in a lower lactate-pyruvate ratio, fewer 
metabolic crises and lower ICP (46). But what about therapeutic hypothermia as a primary 
treatment modality – not just for fever control? Mild hypothermia has been shown to 
decrease cytotoxic edema, lactate accumulation and improve the metabolic stress response 
to SAH in rats (47). It has also been shown to lower ICP and improve outcomes in rats, 
including decreased neurologic deficits (48). In a dog model of SAH, therapeutic 
hypothermia decreased cerebral vasospasm, possibly by decreasing the rise in endothelin-1 
and lessening the decrease of NO in CSF and the blood (49). In patients with SAH treated 
with therapeutic hypothermia, Kawamura used PET scans to demonstrate that hypothermia 
did decrease cerebral blood flow and oxygen metabolic rate (50). Seule et al. treated 100 
patients with SAH who developed intracranial hypertension, symptomatic cerebral 
vasospasm or both, with mild therapeutic hypothermia (51). The majority of these patients 
had poor-grade SAH. 90 patients were evaluated at follow-up, 32 (35.6%) had survived with 
good neurologic outcome (Glasgow Outcome Scale 4 or 5) and 43 (47.8%) died. Side effects 
were common, including electrolyte disorders, pneumonia, thrombocytopenia and septic 
shock. From this study, the authors conclude that therapeutic hypothermia is a viable “last-
resort option”, but side effects are common and potentially severe.  
One of those common side effects of this therapy, shivering, can be detrimental to patients. 
Similar to any condition for which therapeutic hypothermia is employed, shivering should 
be avoided if possible and treated aggressively if present. Shivering has been associated 
with higher oxygen consumption, reduced PbtO2, higher ICP and lower CPP and higher 
resting energy expenditure (52-54). A substudy of the Intraoperative Hypothermia 
Aneurysm Surgery Trial revealed that bradycardia, a common and expected side effect of 
hypothermia, was associated with a higher 3-month mortality rate after SAH. “Relative 
tachycardia” and nonspecific ST-T wave changes, also common with hypothermia therapy, 
were also associated with a mortality difference. The implications of these findings are not 
clear, but should be kept in mind when using this therapeutic approach (55). 
5. Conclusion 
Therapeutic hypothermia has already been shown to have a positive impact on survival and 
neurologic outcome for survivors of out-of-hospital cardiac arrest (2, 3). That benefit likely is 
related to hypothermia’s impact on the multiple mechanisms of secondary brain injury. 
There is certainly potential for therapeutic hypothermia to reduce the secondary injury that 
results from brain and spinal cord injury as well. Many animal studies, but to this point only 
limited clinical studies, have suggested such an effect in treating patients that have suffered 
spinal cord injury, intracerebral hemorrhage or subarachnoid hemorrhage. Fortunately, the 
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technology available to help us achieve and maintain the goals of targeted temperature 
management has made it easier to do so. The availability of that technology and increasing 
familiarity with its use will only serve to help investigators understand the potential impact 
of this therapy in brain and spinal cord injury. Medical therapy for these conditions is 
limited. Hopefully, future studies will clarify the potential role of therapeutic hypothermia 
in improving outcomes for these potentially devastating conditions. 
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